VIR
insider transactionsVir Biotechnology, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-13.6K
0 buy · 13.6K sell
Net value · 30d
-$534.6K
$0 in · $534.6K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
3
0 buy · 13.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director · 10b5-1
$0
10.0K sh
Own New
-
Sell·S
Director · 10b5-1
$500.7K
10.0K sh · $50.07
Own -15%
-
Exercise·M
Director · 10b5-1
$265.2K
10.0K sh · $26.52
Own +18%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own New
-
Sell·S
SVP, Chief Accounting Officer · 10b5-1
$3.6K
379 sh · $9.45
Own -1%
-
Sell·S
Director · 10b5-1
$30.2K
3.2K sh · $9.45
Own -13%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +25%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +49%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +25%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +33%
-
Grant·A
Director
$0
16.0K sh
Own New
-
Grant·A
Director
$0
8.0K sh
Own +60%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Timothy Coughlin 10b5-1 | Exercise M | 10.0K | $0 |
| Jun 12, 2026 | Timothy Coughlin 10b5-1 | Sell S | 10.0K | $500.7K |
| Jun 12, 2026 | Timothy Coughlin 10b5-1 | Exercise M | 10.0K | $265.2K |
| Jun 9, 2026 | Timothy Coughlin | Grant A | 16.0K | $0 |
| Jun 9, 2026 | Timothy Coughlin | Grant A | 8.0K | $0 |
| Jun 1, 2026 | Brent Sabatini 10b5-1 | Sell S | 379 | $3.6K |
| Jun 1, 2026 | Janet Napolitano 10b5-1 | Sell S | 3.2K | $30.2K |
| May 27, 2026 | Charles Elliott Sigal | Grant A | 16.0K | $0 |
| May 27, 2026 | Charles Elliott Sigal | Grant A | 8.0K | $0 |
| May 27, 2026 | Janet Napolitano | Grant A | 16.0K | $0 |
| May 27, 2026 | Janet Napolitano | Grant A | 8.0K | $0 |
| May 27, 2026 | Jeffrey S. Hatfield | Grant A | 16.0K | $0 |
| May 27, 2026 | Jeffrey S. Hatfield | Grant A | 8.0K | $0 |
| May 27, 2026 | Ramy Farid | Grant A | 16.0K | $0 |
| May 27, 2026 | Ramy Farid | Grant A | 8.0K | $0 |
| May 27, 2026 | Norbert W Bischofberger | Grant A | 16.0K | $0 |
| May 27, 2026 | Norbert W Bischofberger | Grant A | 8.0K | $0 |
About VIR insider trading
This page tracks insider transactions for Vir Biotechnology, Inc. (VIR) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.